Prof. Mutlu ARAT

Prof. Dr. Mutlu Arat

Internal Medicine and Hematology Specialist

PERSONAL INFORMATION

• Birth Place / Date: Hamburg, Germany / 1966
• Foreign Languages: English, German

PROFESSIONAL EXPERIENCE

• 2024 – Present , İstanbul, Turkey
  MEMORIAL ŞİŞLİ HOSPITAL
  Internal Medicine and Hematology Specialist
• 2010 – 2013 , İstanbul, Turkey
  İSTANBUL BİLİM UNIVERSITY FACULTY OF MEDICINE – DEPARTMENT OF INTERNAL MEDICINE/HEMATOLOGY
  Professor
• 2010 – 2024 , İstanbul, Turkey
  FLORENCE NIGHTINGALE HOSPITAL ADULT HSCT UNIT
  Director
• 2008 , Minneapolis, USA
  UNIVERSITY OF MINNESOTA – DEPARTMENT OF HEMATOLOGY/BMT UNIT
  Visiting Professor
• 2004 – 2009 , Ankara, Turkey
  ANKARA UNIVERSITY FACULTY OF MEDICINE – DEPARTMENT OF HEMATOLOGY
  Associate Professor
• 2001 – 2004 , Ankara, Turkey
  ANKARA UNIVERSITY FACULTY OF MEDICINE – DEPARTMENT OF HEMATOLOGY
  Hematologist
• 1999 – 2001 , Ankara, Turkey
  ANKARA UNIVERSITY FACULTY OF MEDICINE – DEPARTMENT OF HEMATOLOGY
  Fellow
• 1997 – 1999 , Ankara, Turkey
  ANKARA UNIVERSITY FACULTY OF MEDICINE – DEPARTMENT OF HEMATOLOGY
  Internist
• 1996 – 1997 , Vienna, Austria
  DONAU SPITAL – UNIVERSITY OF VIENNA KMT UNIT
  Observer

EDUCATION

• 2001 – 2003 , Ankara, Turkey
  ANKARA UNIVERSITY FACULTY OF MEDICINE
  Specialization in Hematology
• 1996 – 2001 , Ankara, Turkey
  ANKARA UNIVERSITY FACULTY OF MEDICINE
  Specialization in Internal Medicine
• 1991 – 1996 , Ankara, Turkey
  HACETTEPE UNIVERSITY FACULTY OF MEDICINE
  Medical Doctor (MD)

SCIENTIFIC PUBLICATIONS

1. Bekoz H, et al.
   Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
   Ann Hematol. 2020 Jun 7. doi: 10.1007/s00277-020-04077-4. PMID: 32507911.
2. Nagler A, et al.
   Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation for acute lymphoblastic leukemia.
   Leukemia. 2020 May 11. doi: 10.1038/s41375-020-0850-9. PMID: 32393841.
3. Nagler A, et al.
   Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia.
   Haematologica. 2020 Apr 30. doi: 10.3324/haematol.2020.247296. PMID: 32354866.
4. Penack O, et al.
   Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.
   Lancet Haematol. 2020 Feb;7(2):e157-e167. doi: 10.1016/S2352-3026(19)30256-X. PMID: 32004485.
5. Bazarbachi A, et al.
   Haploidentical transplantation with post-transplantation cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party.
   Biol Blood Marrow Transplant. 2020 May;26(5):936-942. doi: 10.1016/j.bbmt.2020.01.003. PMID: 31926364.
6. Bazarbachi A, et al.
   Influence of donor type, stem cell source, and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP-EBMT study.
   Br J Haematol. 2020 Mar;188(5):745-756. doi: 10.1111/bjh.16182. PMID: 31498883.
7. Mohty M, et al.
   Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group.
   Bone Marrow Transplant. 2020 Mar;55(3):485-495. doi: 10.1038/s41409-019-0705-z. PMID: 31576023.
8. Attal M, et al.
   Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a phase 3 study.
   Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. PMID: 31735560.
9. Domingo-Domènech E, et al.
   Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party.
   Bone Marrow Transplant. 2020 Apr;55(4):796-803. doi: 10.1038/s41409-019-0734-7. PMID: 31695174.
10. Carré M, et al.
    Role of age and hematopoietic cell transplantation-specific comorbidity index in myelodysplastic patients undergoing allotransplant: a retrospective study from the EBMT Chronic Malignancies Working Party.
    Biol Blood Marrow Transplant. 2020 Mar;26(3):451-457. doi: 10.1016/j.bbmt.2019.10.015. PMID: 31647984.

PROFESSIONAL MEMBERSHIPS

• Turkish Journal of Hematology
  • Associate Editor (2004–2011)
• Turkish Apheresis Society
  • Founding Member
  • Chair of the Scientific Committee (2013–2018)
• European Blood and Marrow Transplantation Group (EBMT)
  • LEWP Secretary (2006–2012)
• Joint Accreditation Committee ISHAGE Europe (JACIE)
  • Inspector (Clinic/Collection Facility) (Since August 31, 2004)
• European Hematology Association (EHA)
  • Member (#3873)
  • Education Committee Member (2009–2013)
• American Society of Hematology (ASH)
  • Member (#1001725)
• American Society of Transplantation and Cellular Therapy (ASTCT)
  • Member (#3196)
• Ege Journal of Medicine
  • Review Board Member (Internal Medicine)
• Hematology/Oncology and Stem Cell Therapy
  • International Editorial Board Member